(PDF) OA04 Factors Influencing the Non-Administration of

OA04 Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.014

Full Text

Open PDF

Abstract

Available in full text

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

English

P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations With Non-Adenocartinoma Histology

Journal of Thoracic Oncology

English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

P002 Surgical Resection Improves the Survival of NSCLC Patients With Pleural Metastasis Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P3.13-23 EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion.

Journal of Thoracic Oncology

English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy

English

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

English

Risk Factors of Brain Metastasis During the Course of EGFR-TKIs Therapy for Patients With EGFR-mutated Advanced Lung Adenocarcinoma

Oncotarget

Oncology

2016

English

Amanote Research

OA04 Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.014

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations With Non-Adenocartinoma Histology

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

P002 Surgical Resection Improves the Survival of NSCLC Patients With Pleural Metastasis Treated With First-Line EGFR-TKIs

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

P3.13-23 EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion.

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

Risk Factors of Brain Metastasis During the Course of EGFR-TKIs Therapy for Patients With EGFR-mutated Advanced Lung Adenocarcinoma